TRAEs in all treated patients
| . | N = 30, n (%) . | ||||
|---|---|---|---|---|---|
| Any grade . | Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . | |
| Patients with events | 26 (86.7) | 4 (13.3) | 9 (30.0) | 9 (30.0) | 4 (13.3) |
| Infusion-related reaction* | 9 (30.0) | 1 (3.3) | 6 (20.0) | 2 (6.7) | 0 |
| Nausea | 6 (20.0) | 5 (16.7) | 0 | 1 (3.3) | 0 |
| Alanine aminotransferase increased | 5 (16.7) | 3 (10.0) | 0 | 2 (6.7) | 0 |
| Rash | 5 (16.7) | 4 (13.3) | 1 (3.3) | 0 | 0 |
| Fatigue | 4 (13.3) | 4 (13.3) | 0 | 0 | 0 |
| Aspartate aminotransferase increased | 3 (10.0) | 2 (6.7) | 0 | 1 (3.3) | 0 |
| Back pain | 3 (10.0) | 0 | 2 (6.7) | 1 (3.3) | 0 |
| Blood alkaline phosphatase increased | 3 (10.0) | 0 | 1 (3.3) | 2 (6.7) | 0 |
| Constipation | 3 (10.0) | 3 (10.0) | 0 | 0 | 0 |
| Diarrhea | 3 (10.0) | 3 (10.0) | 0 | 0 | 0 |
| Lipase increased | 3 (10.0) | 0 | 1 (3.3) | 0 | 2 (6.7) |
| Abdominal pain | 2 (6.7) | 2 (6.7) | 0 | 0 | 0 |
| Amylase increased | 2 (6.7) | 0 | 0 | 2 (6.7) | 0 |
| GVHD in liver | 2 (6.7) | 0 | 0 | 2 (6.7) | 0 |
| Biliary sepsis | 1 (3.3) | 0 | 0 | 1 (3.3) | 0 |
| C-reactive protein increased | 1 (3.3) | 0 | 0 | 1 (3.3) | 0 |
| Encephalitis | 1 (3.3) | 0 | 0 | 1 (3.3) | 0 |
| Immune thrombocytopenic purpura | 1 (3.3) | 0 | 0 | 0 | 1 (3.3) |
| Jaundice | 1 (3.3) | 0 | 0 | 1 (3.3) | 0 |
| Orthostatic hypotension | 1 (3.3) | 0 | 0 | 1 (3.3) | 0 |
| Pneumonitis | 1 (3.3) | 0 | 0 | 1 (3.3) | 0 |
| Thrombocytopenia | 1 (3.3) | 0 | 0 | 0 | 1 (3.3) |
| Transaminases increased | 1 (3.3) | 0 | 0 | 1 (3.3) | 0 |
| . | N = 30, n (%) . | ||||
|---|---|---|---|---|---|
| Any grade . | Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . | |
| Patients with events | 26 (86.7) | 4 (13.3) | 9 (30.0) | 9 (30.0) | 4 (13.3) |
| Infusion-related reaction* | 9 (30.0) | 1 (3.3) | 6 (20.0) | 2 (6.7) | 0 |
| Nausea | 6 (20.0) | 5 (16.7) | 0 | 1 (3.3) | 0 |
| Alanine aminotransferase increased | 5 (16.7) | 3 (10.0) | 0 | 2 (6.7) | 0 |
| Rash | 5 (16.7) | 4 (13.3) | 1 (3.3) | 0 | 0 |
| Fatigue | 4 (13.3) | 4 (13.3) | 0 | 0 | 0 |
| Aspartate aminotransferase increased | 3 (10.0) | 2 (6.7) | 0 | 1 (3.3) | 0 |
| Back pain | 3 (10.0) | 0 | 2 (6.7) | 1 (3.3) | 0 |
| Blood alkaline phosphatase increased | 3 (10.0) | 0 | 1 (3.3) | 2 (6.7) | 0 |
| Constipation | 3 (10.0) | 3 (10.0) | 0 | 0 | 0 |
| Diarrhea | 3 (10.0) | 3 (10.0) | 0 | 0 | 0 |
| Lipase increased | 3 (10.0) | 0 | 1 (3.3) | 0 | 2 (6.7) |
| Abdominal pain | 2 (6.7) | 2 (6.7) | 0 | 0 | 0 |
| Amylase increased | 2 (6.7) | 0 | 0 | 2 (6.7) | 0 |
| GVHD in liver | 2 (6.7) | 0 | 0 | 2 (6.7) | 0 |
| Biliary sepsis | 1 (3.3) | 0 | 0 | 1 (3.3) | 0 |
| C-reactive protein increased | 1 (3.3) | 0 | 0 | 1 (3.3) | 0 |
| Encephalitis | 1 (3.3) | 0 | 0 | 1 (3.3) | 0 |
| Immune thrombocytopenic purpura | 1 (3.3) | 0 | 0 | 0 | 1 (3.3) |
| Jaundice | 1 (3.3) | 0 | 0 | 1 (3.3) | 0 |
| Orthostatic hypotension | 1 (3.3) | 0 | 0 | 1 (3.3) | 0 |
| Pneumonitis | 1 (3.3) | 0 | 0 | 1 (3.3) | 0 |
| Thrombocytopenia | 1 (3.3) | 0 | 0 | 0 | 1 (3.3) |
| Transaminases increased | 1 (3.3) | 0 | 0 | 1 (3.3) | 0 |
Events of any grade in ≥2 patients and all grade ≥3 events are shown.
Infusion-related reaction is a composite term that includes infusion-related reaction, back pain, chills, and pyrexia.